PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.
PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.
DURHAM, N.C., Sept. 4, 2013 (SEND2PRESS NEWSWIRE) — HeartIT, the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the NIH in order to develop the ‘Cloud Based Corelab of the Future.’
NEW YORK CITY, N.Y., July 11, 2013 (SEND2PRESS NEWSWIRE) — Stem cell therapy research and treatment will now be available at the Blue Horizon International (BHI) laboratory at the Medissimo Hospital in Bratislava, Slovakia. BHI, along with its local partner, will host a press conference and ribbon-cutting ceremony where its research and treatment lab will […]
MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) — Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) — CMI and Pfizer will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12 in National Harbor, Md.
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) — CMI, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research.
BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — In the early 1980’s George Coleman, head of Dermedics Laboratories in Bridgeport, Conn., teamed up with the former Keneric Industries to reformulate and market an over-the-counter pharmaceutical product designed to treat the symptoms of hangovers. The product, Dr. Seltzer’s Hangover Helper, went on to become the best-selling hangover remedy in the U.S. It was eventually sold to a well-known manufacturer and, after almost 20 years on the market, was discontinued when that manufacturer was sold.
HIGHLAND PARK, N.J., Feb. 1, 2012 (SEND2PRESS NEWSWIRE) — 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere’s staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists.
MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.
MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
NORTH PLAINFIELD, N.J. (SEND2PRESS NEWSWIRE) — For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board’s (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.
MALVERN, Pa. (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled ‘Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer’ (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, which included a Phase II efficacy component and examined progressive dose escalations of Rexin-G.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring forth the benefits of remission in otherwise intractable metastatic cancers.
FORT LAUDERDALE, Fla. (SEND2PRESS NEWSWIRE) — Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in the U.S. and, recently, in Mexico as well. It also has patent protection overseas.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies’ Rexin-G is the world’s smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.
SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.
SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body.
SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.
FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) — The Silver Safety Committee today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver.